Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the publication of results from its Phase 1/2 clinical trial of the novel TROP2 antibody drug conjugate, sacituzumab tirumotecan (sac-TMT), in the Journal of Hematology & Oncology. The study evaluated sac-TMT as a monotherapy in patients with unresectable, locally advanced, or metastatic solid tumors that are refractory to standard therapies. The published results include data from the Phase 1 dose-escalation part, as well as from the Phase 2 expansion cohorts focusing on metastatic triple-negative breast cancer and HR+/HER2− breast cancer. The findings indicate that sac-TMT has a manageable safety profile and promising antitumor activity in these patient populations. Sac-TMT is currently undergoing several Phase 3 studies in China, with global studies led by MSD, which holds exclusive rights outside of Greater China following a licensing agreement in May 2022.